Esophagus News

Treatment options for children with eosinophilic esophagitis have expanded with the FDA’s approval of dupilumab for those aged 1 to 11 years who weigh at least 15 kg, according to a press release.

The FDA has approved the use of dupilumab for treating eosinophilic esophagitis in children aged 1 to 11 years who weigh at least 15 kg, according to a press release.

Researchers reported that on-demand vonoprazan may be a “reasonable alternative” to daily therapy for heartburn, after demonstrating complete and sustained relief of more heartburn episodes than placebo.

VANCOUVER, British Columbia — Once-daily etrasimod 2 mg was well-tolerated and reduced peak eosinophil count at week 16 in patients with eosinophilic esophagitis, according to data presented at the ACG Annual Scientific Meeting.

VANCOUVER, British Columbia — High-dose dupilumab achieved significant improvements in histologic and endoscopic measures through 52 weeks in children aged 1 to 11 years with eosinophilic esophagitis, according to late-breaking data.

The FDA has approved Phathom Pharmaceuticals’ Voquezna tablets 10 mg and 20 mg to treat erosive esophagitis, or erosive gastroesophageal reflux disease, and alleviate heartburn associated with the disease, noted a company release.

HONOLULU — Use of short-acting beta agonists and steroids each raised the likelihood for gastroesophageal reflux disease among firefighters exposed to 9/11 particulate matter, according to a presentation at the CHEST Annual Meeting.

Healthy volunteers taking a first-in-class peptide designed for treating eosinophilic esophagitis did not experience any clinically significant adverse safety findings at any of three evaluated doses, according to a press release.

HONOLULU — Patients with both eosinophilic esophagitis and asthma present to the hospital at an earlier age than those patients who only have EoE, according to an abstract presented at the CHEST Annual Meeting.

The FDA has granted priority review to a supplemental biologics license application for dupilumab in the treatment of children aged 1 to 11 years with eosinophilic esophagitis, according to a press release.